Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Net Margin: 2021-2025

Historic Net Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to 27,873.57%.

  • SAB Biotherapeutics' Net Margin rose 1461122.00% to 27,873.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 62,032.46%, marking a year-over-year increase of 6520858.00%. This contributed to the annual value of -2,579.03% for FY2024, which is 69453.00% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Net Margin stood at 27,873.57% for Q3 2025, which was up 77.33% from 15,718.81% recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Net Margin peaked at 27,873.57% during Q3 2025, and registered a low of -9,934.52% during Q4 2024.
  • Its 3-year average for Net Margin is 3,078.44%, with a median of -532.06% in 2024.
  • As far as peak fluctuations go, SAB Biotherapeutics' Net Margin slumped by 797,092bps in 2023, and later soared by 1,850,651bps in 2025.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Net Margin stood at -104.46% in 2021, then plummeted by 25,996bps to -364.42% in 2022, then slumped by 712,933bps to -7,493.75% in 2023, then plummeted by 244,077bps to -9,934.52% in 2024, then surged by 1,461,122bps to 27,873.57% in 2025.
  • Its Net Margin was 27,873.57% in Q3 2025, compared to 15,718.81% in Q2 2025 and 7,470.38% in Q1 2025.